The management and clinical knowledge of headache disorders among general practitioners in Norway: a questionnaire survey [0.03%]
挪威全科医生对头痛障碍的管理及临床认知：一项调查问卷研究
Espen Saxhaug Kristoffersen,Kashif Waqar Faiz,Jakob Møller Hansen et al.
Espen Saxhaug Kristoffersen et al.
Background: General practitioners (GPs) diagnose and manage a majority of headache patients seeking health care. With the aim to understand the potential for clinical improvement and educational needs, we performed a stud...
Correction to: Clinical symptoms of androgen deficiency in men with migraine or cluster headache: a cross-sectional cohort study [0.03%]
校正：一项关于男性偏头痛或丛集性头痛雄激素不足临床症状的横断面队列研究
Iris E Verhagen,Roemer B Brandt,Carlijn M A Kruitbosch et al.
Iris E Verhagen et al.
Published Erratum
The journal of headache and pain. 2021 Nov 9;22(1):135. DOI:10.1186/s10194-021-01346-z 2021
Pain sensitivity in men who have never experienced a headache: an observer blinded case control study [0.03%]
从未经历过头痛的男性对疼痛的感觉：观察者不知情的对照研究
Isa Amalie Olofsson,Jeppe Hvedstrup,Katrine Falkenberg et al.
Isa Amalie Olofsson et al.
Background: Headache affects 90-99% of the population. Based on the question "Do you think that you never ever in your whole life have had a headache?" 4% of the population say that they have never experienced a headache....
Real-world evidence data on the monoclonal antibody erenumab in migraine prevention: perspectives of treating physicians in Germany [0.03%]
针对偏头痛预防的单克隆抗体erenumab真实世界证据数据：来自德国治疗医生的角度
Andreas Straube,Philipp Stude,Charly Gaul et al.
Andreas Straube et al.
Background: Erenumab, the first-in-class fully human monoclonal antibody targeting the calcitonin gene-related peptide receptor, was shown to be efficacious and safe for the prophylactic treatment of migraine in adults in...
Multicenter Study
The journal of headache and pain. 2021 Nov 6;22(1):133. DOI:10.1186/s10194-021-01344-1 2021
Safety findings from CENTURION, a phase 3 consistency study of lasmiditan for the acute treatment of migraine [0.03%]
III 期CENTURION 研究：lasmiditan作为偏头痛急性治疗药物的疗效和安全性研究结果
C Tassorelli,S Bragg,J H Krege et al.
C Tassorelli et al.
Background: Lasmiditan (LTN) is a selective 5-HT1F receptor agonist for the acute treatment of migraine in adults. We present detailed safety findings from the placebo-controlled, double-blind Phase 3 study, of LTN treatm...
Randomized Controlled Trial
The journal of headache and pain. 2021 Nov 6;22(1):132. DOI:10.1186/s10194-021-01343-2 2021
Correction to: Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study [0.03%]
更正：慢性偏头痛患者接受Erenumab治疗结局不良的心理因素预测：来自开放标签长期前瞻性研究的数据
Sara Bottiroli,Roberto De Icco,Gloria Vaghi et al.
Sara Bottiroli et al.
Published Erratum
The journal of headache and pain. 2021 Nov 3;22(1):131. DOI:10.1186/s10194-021-01342-3 2021
Regional homogeneity alterations in multi-frequency bands in tension-type headache: a resting-state fMRI study [0.03%]
紧张型头痛患者多频段区域同质性改变的休息状态f MRI研究
Shuxian Zhang,Huayun Li,Qinyan Xu et al.
Shuxian Zhang et al.
Objectives: In this study, we aimed to investigate the spontaneous neural activity in the conventional frequency band (0.01-0.08 Hz) and two sub-frequency bands (slow-4: 0.027-0.073 Hz, and slow-5: 0.01-0.027 Hz) in tensi...
CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs [0.03%]
偏头痛的CGRP单克隆抗体与标准预防药物的有效性和耐受性比较
Fenne Vandervorst,Laura Van Deun,Annelies Van Dycke et al.
Fenne Vandervorst et al.
Background: Several drugs are available for the preventive treatment of both episodic and chronic migraine. The choice of which therapy to initiate first, second, or third is not straightforward and is based on multiple f...
Differences in gray matter volume in episodic migraine patients with and without prior diagnosis or clinical care: a cross-sectional study [0.03%]
伴有或不伴先前诊断或临床治疗的发作性偏头痛患者灰质体积的区别：一项横断面研究
Shana A B Burrowes,Olga Goloubeva,Michael L Keaser et al.
Shana A B Burrowes et al.
Background: Migraine sufferers face difficulties getting appropriate care and treatment. Migraine is associated with reduced gray matter volume (GMV) in several brain regions, which could be related to various clinical ch...
Randomized Controlled Trial
The journal of headache and pain. 2021 Oct 23;22(1):127. DOI:10.1186/s10194-021-01340-5 2021
Minimal important change and responsiveness of the Migraine Disability Assessment Score (MIDAS) questionnaire [0.03%]
migraine disability assessment (MIDAS)问卷最小重要差异和反应性分析
Gabriela F Carvalho,Kerstin Luedtke,Tobias Braun
Gabriela F Carvalho
Background: The MIDAS is the most used questionnaire to evaluate migraine-related disability, but its utility to assess treatment response remains unclear. Our aim was to estimate the MIDAS' minimal important change (MIC)...